Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / RARX - Ra Pharma finalizing design of Phase 3 zilucoplan study in myasthenia gravis; shares up 2% premarket


RARX - Ra Pharma finalizing design of Phase 3 zilucoplan study in myasthenia gravis; shares up 2% premarket

  • Ra Pharmaceuticals (NASDAQ:RARX) is up 2% premarket on light volume on the heels of its announcement that it has completed its End-of-Phase 2 interactions with the FDA and is putting the finishing touches on a pivotal Phase 3 study evaluating zilucoplan in patients with generalized myasthenia gravis (gMG), an autoimmune disorder characterized by weakness in the skeletal muscles.
  • More news on: Ra Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,
  • Read more ...
Stock Information

Company Name: Ra Pharmaceuticals Inc.
Stock Symbol: RARX
Market: NASDAQ
Website: rapharma.com

Menu

RARX RARX Quote RARX Short RARX News RARX Articles RARX Message Board
Get RARX Alerts

News, Short Squeeze, Breakout and More Instantly...